$DAVA

Here is Why Endava (DAVA) is One of the Underperforming Tech Stocks to Buy According to Analysts

Endava (NYSE:DAVA) reported FQ3 2026 revenue of £178.5 million, down 8.4% year over year, citing uneven demand and longer deal cycles. The company recorded a £364.6 million goodwill impairment and related tax charges, resulting in a diluted loss per share of £7.55. For FQ4, it expects revenue of £181.0–£185.0 million and adjusted diluted EPS of £0.09–£0.13.

Original reporting
Published Jun 27, 2026, 6:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 27, 2026, 6:53 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Here is Why Endava (DAVA) is One of the Underperforming Tech Stocks to Buy According to Analysts — source image
Decision brief

The 30-second read

$DAVABearishMed
01

Why it matters

Traders can reassess valuation and positioning based on the explicit FQ4 revenue range and next-quarter adjusted diluted EPS range, alongside the AI revenue mix improvement.

02

Market read

Earnings/guidance datapoints (loss, impairment, and forward ranges) dominate the trading setup; AI revenue mix growth is the main offset.

03

What to watch

The article highlights impairment and deferred tax charges but provides limited detail on cash flow, backlog, or margin trajectory—key drivers for whether guidance is a temporary trough.

Relevance 7/10Novelty 6/10Timing: post-FQ3 results with FQ4 revenue and next-quarter adjusted EPS guidance

Background

Endava’s FQ3 2026 update included revenue decline, impairment-related charges, and a strategic pivot toward AI-native delivery.

Company-level read

Ticker impact

$DAVABearishMedium confidence
Context

Endava reported FQ3 2026 revenue down 8.4% YoY and a £364.6M goodwill impairment, plus guided FQ4 revenue and EPS ranges.

Expected impact

Near-term downside bias as guidance implies continued YoY revenue decline and EPS weakness, partially offset by rising AI-native revenue share.

Evidence & confidence

The text includes specific quarterly results and forward ranges (revenue £181.0–£185.0M; adjusted diluted EPS £0.09–£0.13) plus large impairment/loss figures, which typically drive trading around earnings/guidance.

Market effects

Signals ongoing pressure in digital transformation/IT services demand cycles, while AI-native delivery is being positioned as a partial growth offset.

Primarily impacts UK-headquartered tech services sentiment and UK-listed investor perception of AI services monetization.

Read-across for global IT services peers on deal-cycle length and AI-driven revenue mix transition.

Counterpoint

AI-native revenue share rising from 5% to 15% could eventually stabilize growth even if near-term revenue and EPS remain weak.

Key entities

  • Endava

    Reported FQ3 2026 results with revenue down 8.4% YoY, £364.6M goodwill impairment, and provided FQ4 revenue and next-quarter adjusted EPS guidance.

  • Mastercard

    Named as a new partnership supporting Endava’s AI-driven business growth.

  • NatWest

    Named as part of a partnership (via Tyl) supporting Endava’s AI-driven business growth.

Related articles

$MURMedAI 8/10

Murphy Oil Sees Sharp Profit Increase

Murphy Oil Corp reported Q2 2026 adjusted net income of $225.8 million, nearly six times Q2 2025, as higher oil prices offset lower production and weaker gas. Adjusted EPS was $1.55 vs $1.51 consensus. Revenue rose to $926.3 million. Murphy kept its $0.35 dividend and raised 2026 capex midpoint to $1.55 billion.

$GSBDMed

Goldman Sachs BDC Q2 Earnings Call Highlights

Goldman Sachs BDC (NYSE:GSBD) reported no incentive fee in Q2, citing its three-year total-return lookback provision. NAV was $12.06/share at June 30 vs $12.17 in Q1. The board declared a Q3 base dividend of $0.32/share plus $0.03 supplemental. Investments were $3.2B fair value, non-accrual 2.9%, and net debt-to-equity 1.35x.

$HBBMed

Hamilton Beach Brands Q2 Earnings Call Highlights

Hamilton Beach Brands (HBB) reported Q2 gross margin of 26.1% excluding tariff-related benefits, and said it expects 2026 revenue growth in the mid-single-digit range. Management forecast full-year gross margin to improve modestly and operating profit to decline by a high-single-digit percentage. Operating cash flow is expected at $35M to $45M. HBB ended with net cash of $51.5M.

$GXOMed

GXO Logistics Q2 Earnings Call Highlights

GXO Logistics reported Q2 results and said it secured over $1 billion in expected incremental new-business revenue for 2026 and about $353 million for 2027. Management cited a $2.7 billion sales pipeline after quarter end. Operating cash flow was $76 million, free cash flow positive $12 million, cash $769 million, and net leverage 2.6x. GXO plans to target EBIT margins above 6% and deploy AI across ~50 sites in 2026.

$GRNDMed

Grindr Q2 Earnings Call Highlights

Grindr (NYSE:GRND) said free users remain central to its strategy, while AI tools are boosting engineering productivity. Management estimated engineering output rose about 2.5x from July 2025 to April 2026 with similar headcount, supporting a 39% to 42% adjusted EBITDA margin outlook. EDGE AI premium tier rollout is planned for later in fall; operating expenses ex cost of revenue were $71M vs $53M.

$HAEMedAI 8/10

Haemonetics Q1 Earnings Call Highlights

Haemonetics (NYSE:HAE) reported Q1 interventional technologies returning to 3% organic growth, with vascular closure led by VASCADE MVP and MVP XL momentum in the U.S. Apheresis revenue rose 6% organically to $191M and plasma revenue grew 8% organically as Persona PLUS rollout accelerates. Haemonetics raised FY2027 revenue guidance to 5% to 8% reported and 4% to 7% organic.